| Literature DB >> 15115540 |
Diego G Silva1, Christian Schönbach, Vladimir Brusic, Luis A Socha, Takeshi Nagashima, Nikolai Petrovsky.
Abstract
BACKGROUND: A major goal in the post-genomic era is to identify and characterise disease susceptibility genes and to apply this knowledge to disease prevention and treatment. Rodents and humans have remarkably similar genomes and share closely related biochemical, physiological and pathological pathways. In this work we utilised the latest information on the mouse transcriptome as revealed by the RIKEN FANTOM2 project to identify novel human disease-related candidate genes. We define a new term "patholog" to mean a homolog of a human disease-related gene encoding a product (transcript, anti-sense or protein) potentially relevant to disease. Rather than just focus on Mendelian inheritance, we applied the analysis to all potential pathologs regardless of their inheritance pattern.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15115540 PMCID: PMC420239 DOI: 10.1186/1471-2164-5-28
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Flow chart of method used for the identification of "pathologs". Obtained from the FANTOM2 dataset, "similar to" clones were analysed using a manual (left) and a semi-automated approach (right) to identify "patholog" genes. HDR clones: clones with Human Disease Relationship.
Novel potential "pathologs" classified by type of human disorder and relationship to the disease process.
| Cancer | 61 | 19 | 16 | |
| Hereditary | 39 | 4 | 0 | |
| Immunological | 5 | 5 | 0 | |
| Cardio-vascular | 8 | 0 | 0 | |
| Reproductive | 6 | 0 | 0 | |
| Other | 17 | 0 | 2 | |
Cancer related pathologs. Representative disease is shown for each clone. * RTPS6.3 (representative transcript protein set 6.3) cluster representative transcriptional unit (TU) of the FANTOM2 clone set. OMIM status: 1 = gene present in OMIM with a reported disease; 2 = gene present in OMIM with different disease association or without disease; 3 = gene not present in OMIM.
| | |||||
| 1110013A16* | AK003650 | Squamous cell carcinoma | 1 | ||
| 1300012C15* | AK004970 | Gynecologic malignancies | 2 | ||
| 1600002M22* | AK005400 | Trophoblastic disease, tumour marker | 1 | ||
| 1810011L16* | AK007436 | Hereditary renal tumors | 3 | ||
| 2310046E09 | AK009843 | Chronic lymphocytic leukemia | 2 | ||
| 2600013I19* | AK011199 | Prognosis of neoplastic diseases | 2 | ||
| 4631401E18* | AK019470 | Colorectal carcinoma | 2 | ||
| 4930435F02 | AK019597 | Breast cancer | 3 | ||
| 4932411D20* | AK029960 | T-cell based immunotherapy | 3 | ||
| 5330423N11* | AK077331 | Cutaneous malignant melanoma | 3 | ||
| 9130023H10* | AK033603 | Melanoma | 3 | ||
| 9130413M24* | AK078964 | T-cell based immunotherapy | 3 | ||
| 9330156N18* | AK034104 | Paraneoplastic pemphigus | 2 | ||
| A030012E10* | AK037235 | Squamous cell carcinoma | 3 | ||
| A230060D07* | AK038754 | Chronic myelogenous leukemia | 3 | ||
| A430037M23 | AK039975 | Endometrial neoplasms | 2 | ||
| A630051G17 | AK080312 | Meningioma and glioma | 1 | ||
| E130307D12* | AK087504 | Breast cancer | 1 | ||
| G430124K07* | AK090101 | Lung carcinoma | 3 | ||
| | |||||
| 0610006O14 | AK002260 | Melanoma | 2 | ||
| 0610008P16* | AK002360 | Hepatocellular carcinoma | 3 | ||
| 1110068E08* | AK004405 | Gliomas | 3 | ||
| 1200003O15* | AK004587 | Leukaemia | 1 | ||
| 1500012D09 | AK005230 | Nasopharyngeal carcinoma | 1 | ||
| 1700001P03* | AK005620 | Colon cancer | 1 | ||
| 1700006L01 | Multiple myeloma | 2 | |||
| 1700012B18* | AK005892 | Breast cancer | 3 | ||
| 1700045I19* | AK006700 | Prostate cancer | 2 | ||
| 1810017F10* | AK007525 | Tumour-associated antigen | 3 | ||
| 2010003F10* | AK008064 | Pancreatic cancer | 1 | ||
| 2210006M16* | AK008663 | Human gastric cancer cells | 3 | ||
| 2210007N23 | AK019050 | Gastric carcinogenesis | 1 | ||
| 2210412D05 | AK008907 | Acute myeloid leukaemia | 1 | ||
| 2210414K06 | AK008928 | Cell metastasis and malignant transformation | 2 | ||
| 2310016C08* | AK009377 | Cervix cancer | 3 | ||
| 2510002J07* | AK010891 | Cancers and inflammation-associated diseases. | 2 | ||
| 2610002I10 | AK011289 | Tumourigenesis | 3 | ||
| 2610005L07 | AK011323 | Cancer development | 1 | ||
| 2700048G21* | AK012392 | Colon cancer antigen | 3 | ||
| 2810411G23 | AK013085 | Breast cancer | 1 | ||
| 2810425C21* | AK013153 | Non-small cell lung cancer | 2 | ||
| 2810449N18* | AK013316 | Thyroid carcinoma | 2 | ||
| 2900009D12 | AK013503 | Hereditary paraganglioma | 1 | ||
| 4432412E01* | AK014491 | Bladder-cancer | 2 | ||
| 4631410F01 | AK028459 | Gastric carcinomas | 3 | ||
| 4732440A06* | AK028704 | Breast cancer, metastasis | 2 | ||
| 4930500E24* | AK019661 | Central nervous system tumours | 3 | ||
| 4932436B18* | AK030081 | Prostate cancer | 1 | ||
| 4933405E14* | AK016662 | Tumour suppressor | 3 | ||
| 4933409E02* | AK016751 | Colon cancer cell line | 3 | ||
| 5430417G24* | AK030670 | Squamous cell carcinoma | 1 | ||
| 5630400A09* | AK030708 | Basal cell and squamous cell carcinomas | 1 | ||
| 5730484M20* | AK077629 | Lung cancer | 1 | ||
| 6430531D06* | AK032385 | Capillary thyroid carcinoma | 1 | ||
| 6430587E11 | AK032541 | Breast cancer | 1 | ||
| 6820401K01* | AK033012 | Cancer development | 2 | ||
| 9330137N20 | AK079068 | Lymphoblastic leukaemia | 1 | ||
| 9330200A01* | AK034492 | Squamous non-small cell lung carcinoma | 2 | ||
| A130080E24* | AK038118 | Colon tumour | 3 | ||
| A430025E01* | AK039888 | Colorectal tumours | 2 | ||
| A430075F05 | AK040185 | Acute myeloid leukaemia | 1 | ||
| A730042E07 | AK042943 | Melanoma | 2 | ||
| A830098D13* | AK044188 | Acute megakaryoblastic leukemias | 1 | ||
| A930033B01 | AK020920 | Hematopoeitic disorders | 1 | ||
| B130017M24 | AK044984 | Hepatocellular carcinoma | 3 | ||
| B230314N17 | AK045848 | Carcinogenesis | 1 | ||
| B930026D14* | AK047144 | Prostate carcinoma | 3 | ||
| B930095M03* | AK081171 | Gastric cancer | 1 | ||
| C130050F24* | AK048341 | Colorectal carcinoma | 2 | ||
| C130062I06* | AK048462 | Hepatocellular carcinoma | 1 | ||
| C230012L01 | AK048706 | Prostate cancer | 1 | ||
| C630001O15 | AK049821 | MALT lymphoma | 1 | ||
| D330038I09 | AK052361 | Tumour cells | 2 | ||
| E030001H09* | AK086788 | Glioblastoma multiforme | 1 | ||
| E030027H19* | AK087108 | Human colorectal cancer | 3 | ||
| E230037B21 | AK054229 | Several tumour types | 3 | ||
| F630110I03 | AK089273 | Colon carcinomas or brain tumours | 3 | ||
| F730035A01 | AK089461 | Malignant rhabdoid tumours | 1 | ||
| G630018E19* | AK090207 | Prostate cancer | 1 | ||
| G630034H08* | AK090280 | Small cell lung cancer | 3 | ||
| | |||||
| 1100001P14 | AK075618 | Human colon adenocarcinoma | 3 | ||
| 1200012D01* | AK004723 | Angiogenesis | 3 | ||
| 1810010L20 | AK075773 | Pituitary adenomas | 2 | ||
| 2310039D24* | AK009689 | Solid tumours | 1 | ||
| 2600009M07 | AK011174 | Antineoplastic activity | 3 | ||
| 2810459H04 | AK013366 | Angiogenesis | 1 | ||
| 3010033I09* | AK019405 | Tumours originating from epithelial tissue | 1 | ||
| 5730405M22* | AK077421 | Glioma | 2 | ||
| 6030493E19 | AK031701 | Melanoma | 1 | ||
| 6230424I22* | AK031785 | Tumor suppression | 2 | ||
| A730016J02 | AK042696 | Vascular and haematopoietic development | 3 | ||
| B130023J22 | AK045057 | Breast cancer | 3 | ||
| C920008O22 | AK050594 | Breast cancer | 2 | ||
| D030050C19 | AK083587 | Leukemias and tumour cell lines | 1 | ||
| D630010E08* | AK052639 | Cancer tumour cells | 1 | ||
| D830007E07* | AK052857 | Ovarian cancer | 2 | ||
Pathologs related to hereditary disorders. Representative disease is shown for each clone. * RTPS6.3 (representative transcript protein set 6.3) cluster representative transcriptional unit (TU) of the FANTOM2 clone set. OMIM status: 1 = gene present in OMIM with a reported disease; 2 = gene present in OMIM with different disease association or without disease; 3 = gene not present in OMIM.
| | |||||
| 1700026F24 | AK006381 | Neurogenetic disorders | 3 | ||
| 2300002L19* | AK009012 | Gaucher's disease | 1 | ||
| 2700028P07 | AK012300 | Creutzfeldt-Jakob disease | 3 | ||
| 4732420G08* | AK028628 | Methionine synthase reductase deficiency | 1 | ||
| | |||||
| 1010001M04* | AK003132 | Mitochondrial complex I deficiency | 1 | ||
| 1110019I12* | AK003819 | Congenital muscular dystrophy | 1 | ||
| 4930414M06 | AK005847 | Peroxisomal D-hydroxyacyl-CoA dehydrogenase deficiency | 1 | ||
| 1810064C02 | AK007951 | Spondyloepiphyseal dysplasia tarda | 1 | ||
| 2310057L06 | AK075908 | Retinitis pigmentosa | 2 | ||
| 2410004F01* | AK010385 | Charcot-marie-tooth disease | 1 | ||
| 2610205J09 | AK011891 | Progressive myoclonus epilepsy | 1 | ||
| 2900072D10* | AK013765 | Cardioencephalomyopathy and a severe COX deficiency | 1 | ||
| 3110031I02* | AK014104 | Wiskott-Aldrich syndrome | 1 | ||
| 4832440C16 | AK029338 | Ocular albinism type 1 | 1 | ||
| 4930430B17 | AK076748 | Machado-joseph disease | 1 | ||
| 5830404H04 | AK017896 | Autoimmune polyglandular disease type I | 1 | ||
| 6030476O14 | AK031666 | Muscular dystrophy and cardiomyopathy | 1 | ||
| 6430516P20 | AK032293 | Late infantile neuronal ceroid lipofuscinosis | 1 | ||
| 6430560A18 | AK078275 | Barth syndrome and chondrodysplasia punctata | 2 | ||
| 8030487I16 | AK033295 | Leukocyte adhesion deficiency II | 1 | ||
| 9330166I04* | AK034236 | Sialidosis | 1 | ||
| 6720416P20* | AK032725 | MEN2a MEN2b | 1 | ||
| 9630046L06 | AK036225 | Glycogen storage disease type III | 1 | ||
| 9930121L06* | AK037126 | Athabascan SCID | 3 | ||
| A130054J05* | AK037846 | Velo-cardio-facial syndrome | 1 | ||
| A230074J06* | AK038912 | X-linked congenital stationary night blindness | 1 | ||
| A230090N11* | AK039054 | Cylindromatosis | 1 | ||
| A630004L17 | AK041354 | Deafness | 3 | ||
| A730020L24 | AK042745 | Zellweger syndrome | 1 | ||
| A830020B12 | AK043682 | Peroxisome-biogenesis disorders | 1 | ||
| A930007F16 | AK044320 | Lowe syndrome | 1 | ||
| A930014F04 | AK044460 | Friedreich's ataxia | 1 | ||
| B230307C21* | AK045712 | Progressive myoclonus epilepsy | 1 | ||
| B230311E17 | AK045797 | Mitochondrial myopathies | 2 | ||
| B430307M20* | AK046679 | Spinocerebellar ataxia type 7 | 1 | ||
| C130020P08 | AK047906 | Oculocerebrorenal syndrome of Lowe | 1 | ||
| C330001M22* | AK049106 | Autosomal recessive deafness | 2 | ||
| C330016K18* | AK049248 | Proximal renal tubular acidosis associated with ocular abnormalities | 1 | ||
| C430015N23* | AK049478 | Lysinuric protein intolerance | 1 | ||
| D030003E11 | AK050684 | Progeroid type Ehlers-Danlos syndrome | 1 | ||
| E130016P05 | AK084312 | Cleft palate | 1 | ||
| D630003K02* | AK085272 | Methemoglobinemia | 1 | ||
| D630025L11* | AK052697 | Chorea-acanthocytosis | 1 | ||
Pathologs related to other disorders. Representative disease is shown for each clone. *RTPS6.3 (representative transcript protein set 6.3) cluster representative transcriptional unit (TU) of the FANTOM2 clone set. OMIM status: 1 = gene present in OMIM with a reported disease; 2 = gene present in OMIM with different disease association or without disease; 3 = gene not present in OMIM.
| | |||||
| 1500019E10* | AK005285 | Systemic lupus erythematosus | 1 | ||
| 1810019E15 | AK007546 | LES and Juvenile RA | 2 | ||
| 2700059D02* | AK012454 | Behecet's Disease, sarcoidosis and Vogt-Koyanagi-Harada disease | 3 | ||
| 4632415P04* | AK028516 | Sjogren's syndrome | 1 | ||
| D030032G01* | AK050903 | Systemic lupus erythematosus | 2 | ||
| | |||||
| A630006E02* | AK041380 | Graft-versus-host disease | 1 | ||
| B230303A05* | AK045681 | Autoimmunity to U1 snrnps | 1 | ||
| B230397K24* | AK046480 | Rheumatoid arthritis | 3 | ||
| C330006A15* | AK049133 | Scleroderma autoimmune antigens | 1 | ||
| F830032C23* | AK089843 | Crohn's disease | 1 | ||
| | |||||
| 2210420D18 | Alzheimer's disease | 2 | |||
| 4833420A15 | AK014731 | Huntington's disease | 1 | ||
| 9330170I02* | AK034263 | Alzheimer's disease | 2 | ||
| B230307E07 | AK045716 | Alzheimer's disease | 3 | ||
| | |||||
| 1700127D06* | AK007298 | Hypertension | 1 | ||
| 2510048K03* | AK011112 | Essential hypertension | 1 | ||
| 4833405G23 | AK029362 | Ischemic diseases | 3 | ||
| 9630044I02 | AK036182 | Cardiomyopathy | 3 | ||
| B430208E24* | AK046620 | Neuropathology of ischemia | 2 | ||
| D130064D17* | AK051677 | Essential hypertension | 3 | ||
| E030024D09* | AK087056 | Hypertension | 1 | ||
| 2310063B19* | AK010021 | Hhypertension | 2 | ||
| | |||||
| 0610007H07* | Fetal loss | 3 | |||
| 1700010P14* | AK005852 | Spermatogenesis | 3 | ||
| 4631410O16* | AK028461 | Reproduction | 1 | ||
| 4930406H24* | AK029590 | Spermatogenesis | 3 | ||
| B130010I06* | AK044891 | Sex differentiation disorders | 3 | ||
| D030049L20 | AK050982 | Immunologic infertility | 1 | ||
| | |||||
| 1110004H01* | AK003421 | Fracture healing | 3 | ||
| 1810015E19 | AK007508 | Autism | 1 | ||
| 1810015M19* | AK019013 | Sickle cell disease | 1 | ||
| 4932434G09* | AK016547 | Connective tissue diseases | 3 | ||
| 5730465G20 | AK077598 | Blood group I gene | 3 | ||
| 9830131G07* | AK036537 | Hematopoiesis | 2 | ||
| 9930031F20 | AK036967 | Type 2 diabetes | 3 | ||
| A130042M24* | AK037730 | COPD | 1 | ||
| A730076H11 | AK043253 | Leishmania major | 3 | ||
| A830007N20 | AK043557 | Triple-A syndrome | 1 | ||
| B830002B15* | AK046772 | Cystic diseases | 1 | ||
| C230099M23* | AK082743 | Schizophrenia | 3 | ||
| E130216C05 | AK087459 | Healing corneal epithelium | 2 | ||
| | |||||
| 5033405N08* | AK017155 | Chronic pain, addictive states and brain injury | 3 | ||
| A930028N13 | AK044634 | Human hemolytic anemias | 2 | ||
Figure 2Flow chart of method used to classify "pathologs". To identify pathologs that correspond to already known mouse orthologs or potential new orthologs, cDNA sequences were compared to known human sequences and conservation of synteny assessed using mouse to human mapping information. If the patholog corresponded to best mouse to human hit the reported function of the gene product was checked. Mouse sequences with reported human ortholog and known function were classified as "known ortholog", sequences reported as best mouse to human hit with unknown function were classified as "ortholog-candidate" and sequences with unknown function that did not correspond to the best mouse to human hit were classified as "novel sequences".
Comparison of the OMIM entries (July 2003) with pathologs. "OMIM NDA" stands for pathology entries that are in OMIM, but disease association was not specified, or it was not consistent with the disease specified in PubMed abstracts. "OMIM DA" stands for pathologs that match both OMIM entries and disease association.
| Cancer | 26 | 33 | 37 | 96 |
| Hereditary disorders | 4 | 4 | 35 | 43 |
| Other | 9 | 17 | 17 | 43 |
| Total | 39 | 54 | 89 | 182 |